Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
Past, Present, and Future of AI with Vijay Pande
Fireside Chat with Sean Duffy
Introducing: Raising Health
Generalist Medical AI with Pranav Rajpurkar
Gate Unveiling with Jordi Mata-Fink
How to Build an AI-Native Health Plan with Mario Schlosser
Bridging AI, Ethics, and Consumer Trust with Miriam Vogel
Clinical Copilots: Augmenting Human Care with Suchi Saria
The Worlds She Sees with Fei-Fei Li
Supercharging Discovery with Evan Feinberg
Evolving Biotechnologies with Olga Troyanskaya
CMO vs. CPO with Peter Shalek and Reena Pande
Interpretability and the AI "Clear Box" with Surya Ganguli
AI Revolution with Daphne Koller
When Quantity Becomes Quality with Aviv Regev
Navigating the Future of AI with Andrew Ng
Unleashing CAR T with Carl June
Becoming a Partnership Pioneer with Dan Nomura
Wartime and Peacetime: Being a Leader with Ben Horowitz
Medical Education and AI with Lloyd B. Minor
Create your
podcast in
minutes
It is Free